Top

Published in:

Open Access 01-12-2016 | Review

Paraproteinemic neuropathy: a practical review

Authors: Richard A. Rison, Said R. Beydoun

Published in: BMC Neurology | Issue 1/2016

Abstract

The term paraproteinemic neuropathy describes a heterogeneous set of neuropathies characterized by the presence of homogeneous immunoglobulin in the serum. An abnormal clonal proliferation of B-lymphocytes or plasma cells, which may or may not occur in the context of a hematologic malignancy, produces the immunoglobulins in excess. If malignancy is identified, treatment should be targeted to the neoplasm. Most cases, however, occur as monoclonal gammopathy of undetermined significance. Few prospective, randomized, placebo-controlled trials are available to inform the management of paraproteinemic neuropathies. Clinical experience combined with data from smaller, uncontrolled studies provide a basis for recommendations, which depend on the specific clinical setting in which the paraprotein occurs. In this review, we provide a clinically practical approach to diagnosis and management of such patients.

Rajabally YA. Neuropathy and paraproteins: review of a complex association. Eur J Neurol. 2011;18(11):1291–8. doi:10.1111/j.1468-1331.2011.03380.x.CrossRefPubMed

Zivkovic SA, Lacomis D, Lentzsch S. Paraproteinemic neuropathy. Leuk Lymphoma. 2009;50(9):1422–33. doi:10.1080/10428190903111922.CrossRefPubMed

Kwan JY. Paraproteinemic neuropathy. Neurol Clin. 2007;25(1):47–69. doi:10.1016/j.ncl.2006.12.002.CrossRefPubMed

Rojas-Garcia R, Gallardo E, Illa I. Paraproteinemic neuropathies. Presse medicale (Paris, France: 1983). 2013;42(6 Pt 2):e225–34. doi:10.1016/j.lpm.2013.02.329.CrossRef

Martyn CN, Hughes RA. Epidemiology of peripheral neuropathy. J Neurol Neurosurg Psychiatry. 1997;62(4):310–8.CrossRefPubMedPubMedCentral

Kelly Jr JJ, Kyle RA, O’Brien PC, Dyck PJ. Prevalence of monoclonal protein in peripheral neuropathy. Neurology. 1981;31(11):1480–3.CrossRefPubMed

Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistere, France. J Clin Pathol. 1982;35(1):63–8.CrossRefPubMedPubMedCentral

Gosselin S, Kyle RA, Dyck PJ. Neuropathy associated with monoclonal gammopathies of undetermined significance. Ann Neurol. 1991;30(1):54–61. doi:10.1002/ana.410300111.CrossRefPubMed

Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9. doi:10.1056/NEJMoa054494.CrossRefPubMed

10.

Crawford J, Eye MK, Cohen HJ. Evaluation of monoclonal gammopathies in the “well” elderly. Am J Med. 1987;82(1):39–45.CrossRefPubMed

11.

International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121(5):749–57.CrossRef

12.

Gorson KC. An update on the management of chronic inflammatory demyelinating polyneuropathy. Ther Adv Neurol Disord. 2012;5(6):359–73. doi:10.1177/1756285612457215.CrossRefPubMedPubMedCentral

13.

Shah D, Seiter K. Multiple Myeloma. 2015. http://emedicine.medscape.com/article/204369-overview-showall.

14.

Kyle R, Dyck PJ. Neuropathy associated with the monoclonal gammopathies. In: Dyck PJ, Thomas PK, editors. Peripheral Neuropathy. 4th ed. Philadelphia: Elsevier Saunders; 2005. p. 2255–76.CrossRef

15.

Nobile-Orazio E, Barbieri S, Baldini L, Marmiroli P, Carpo M, Premoselli S, et al. Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta Neurol Scand. 1992;85(6):383–90.CrossRefPubMed

16.

Rison RA, Beydoun SR. Amyotrophic lateral sclerosis-motor neuron disease, monoclonal gammopathy, hyperparathyroidism, and B12 deficiency: case report and review of the literature. J Med Case Reports. 2010;4:298. doi:10.1186/1752-1947-4-298.CrossRefPubMedCentral

17.

Gorson KC. Clinical features, evaluation, and treatment of patients with polyneuropathy associated with monoclonal gammopathy of undetermined significance (MGUS). J Clin Apher. 1999;14(3):149–53.CrossRefPubMed

18.

Niermeijer JM, Fischer K, Eurelings M, Franssen H, Wokke JH, Notermans NC. Prognosis of polyneuropathy due to IgM monoclonal gammopathy: a prospective cohort study. Neurology. 2010;74(5):406–12. doi:10.1212/WNL.0b013e3181ccc6b9.CrossRefPubMed

19.

Hadden RD, Nobile-Orazio E, Sommer C. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on Management of Paraproteinaemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Periph Nerv. 2010;15:185–95.CrossRef

20.

Ferri C, La Civita L, Cirafisi C, Siciliano G, Longombardo G, Bombardieri S, et al. Peripheral neuropathy in mixed cryoglobulinemia: clinical and electrophysiologic investigations. J Rheumatol. 1992;19(6):889–95.PubMed

21.

Caniatti LM, Tugnoli V, Eleopra R, Tralli G, Bassi R, De Grandis D. Cryoglobulinemic neuropathy related to hepatitis C virus infection. Clinical, laboratory and neurophysiological study. J Peripher Nerv Syst. 1996;1(2):131–8.PubMed

22.

Garcia-Bragado F, Fernandez JM, Navarro C, Villar M, Bonaventura I. Peripheral neuropathy in essential mixed cryoglobulinemia. Arch Neurol. 1988;45(11):1210–4.CrossRefPubMed

23.

Kyle RA, Gertz MA. Systemic amyloidosis. Crit Rev Oncol Hematol. 1990;10(1):49–87.CrossRefPubMed

24.

Benson MD, Kincaid JC. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve. 2007;36(4):411–23. doi:10.1002/mus.20821.CrossRefPubMed

25.

Beydoun SR, Rison RA, Commins D. Secondary amyloidosis as a life-ending event in multifocal motor neuropathy. Muscle Nerve. 2001;24(10):1396–402.CrossRefPubMed

26.

Willison HJ, O’Leary CP, Veitch J, Blumhardt LD, Busby M, Donaghy M, et al. The clinical and laboratory features of chronic sensory ataxic neuropathy with anti-disialosyl IgM antibodies. Brain. 2001;124(Pt 10):1968–77.CrossRefPubMed

27.

Delmont E, Jeandel PY, Hubert AM, Marcq L, Boucraut J, Desnuelle C. Successful treatment with rituximab of one patient with CANOMAD neuropathy. J Neurol. 2010;257(4):655–7. doi:10.1007/s00415-009-5412-z.CrossRefPubMed

28.

Dispenzieri A, Suarez GA, Kyle R. POEMS syndrome. In: Dyck PJ, Thomas P, editors. Peripheral Neuropathy. 4th ed. Philadelphia: Elsevier Sanders; 2005. p. 2453–69.CrossRef

29.

Rison RA. Papilloedema and hypertrichosis: the varied and harried manifestations of POEMS syndrome. BMJ case reports. 2009. doi:10.1136/bcr.09.2008.1000.

30.

Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med. 1994;97(6):543–53.CrossRefPubMed

31.

Kuwabara S, Dispenzieri A, Arimura K, Misawa S, Nakaseko C. Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome. Cochrane Database Syst Rev. 2012;6:Cd006828. doi:10.1002/14651858.CD006828.pub3.PubMed

32.

Viala K, Behin A, Maisonobe T, Leger JM, Stojkovic T, Davi F, et al. Neuropathy in lymphoma: a relationship between the pattern of neuropathy, type of lymphoma and prognosis? J Neurol Neurosurg Psychiatry. 2008;79(7):778–82. doi:10.1136/jnnp.2007.125930.CrossRefPubMed

33.

Kelly JJ, Karcher DS. Lymphoma and peripheral neuropathy: a clinical review. Muscle Nerve. 2005;31(3):301–13. doi:10.1002/mus.20163.CrossRefPubMed

34.

Viala K, Maisonobe T, Stojkovic T, Koutlidis R, Ayrignac X, Musset L, et al. A current view of the diagnosis, clinical variants, response to treatment and prognosis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst. 2010;15(1):50–6. doi:10.1111/j.1529-8027.2010.00251.x.CrossRefPubMed

35.

Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA. Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve. 2009;39(4):432–8. doi:10.1002/mus.21206.CrossRefPubMed

36.

Yeung KB, Thomas PK, King RH, Waddy H, Will RG, Hughes RA, et al. The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol. 1991;238(7):383–91.CrossRefPubMed

37.

D’Souza A, Hayman SR, Buadi F, Mauermann M, Lacy MQ, Gertz MA, et al. The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome. Blood. 2011;118(17):4663–5. doi:10.1182/blood-2011-06-362392.CrossRefPubMed

38.

Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010;24(6):1121–7. doi:10.1038/leu.2010.60.CrossRefPubMed

39.

Fanning S, Hussein M. Monoclonal Gammopathies of Uncertain Origin. 2014. Medscape, http://emedicine.medscape.com/article/204297-medication. Accessed September 18, 2015.

40.

Vital A. Paraproteinemic neuropathies. Brain Pathol (Zurich, Switzerland). 2001;11(4):399–407.CrossRef

41.

Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev. 2012;5:Cd002827. doi:10.1002/14651858.CD002827.pub3.PubMed

42.

Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol. 1996;40(5):792–5. doi:10.1002/ana.410400516.CrossRefPubMed

43.

Nobile-Orazio E, Meucci N, Baldini L, Di Troia A, Scarlato G. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain. 2000;123(Pt 4):710–7.CrossRefPubMed

44.

Gorson KC, Ropper AH, Weinberg DH, Weinstein R. Treatment experience in patients with anti-myelin-associated glycoprotein neuropathy. Muscle Nerve. 2001;24(6):778–86.CrossRefPubMed

45.

Comi G, Roveri L, Swan A, Willison H, Bojar M, Illa I, et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol. 2002;249(10):1370–7. doi:10.1007/s00415-002-0808-z.CrossRefPubMed

46.

Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial. 2003;7(2):155–60.CrossRefPubMed

47.

Stork AC, Lunn MP, Nobile-Orazio E, Notermans NC. Treatment for IgG and IgA paraproteinaemic neuropathy. Cochrane Database Syst Rev. 2015;3:Cd005376. doi:10.1002/14651858.CD005376.pub3.PubMed

48.

Shepherd JE, Grabenstein JD. Immunizations for high-risk populations. J Am Pharm Assoc. 2001;41(6):839–49. quiz 923-835.CrossRef

49.

Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence (1993). MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports/Centers for Disease Control 42 (Rr-4):1-18

50.

Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol. 2009;65(3):286–93. doi:10.1002/ana.21577.CrossRefPubMed

51.

Leger JM, Viala K, Nicolas G, Creange A, Vallat JM, Pouget J, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy. Neurology. 2013;80(24):2217–25. doi:10.1212/WNL.0b013e318296e92b.CrossRefPubMedPubMedCentral

52.

Treon SP, Branagan AR, Hunter Z, Santos D, Tournhilac O, Anderson KC. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemia. Ann Oncol. 2004;15(10):1481–3. doi:10.1093/annonc/mdh403.CrossRefPubMed

53.

Kosmidis ML, Dalakas MC. Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord. 2010;3(2):93–105. doi:10.1177/1756285609356135.CrossRefPubMedPubMedCentral

54.

Noronha V, Fynan TM, Duffy T. Flare in neuropathy following rituximab therapy for Waldenstrom’s macroglobulinemia. J Clin Oncol. 2006;24(1), e3. doi:10.1200/jco.2005.04.6474.CrossRefPubMed

55.

Wilson HC, Lunn MP, Schey S, Hughes RA. Successful treatment of IgM paraproteinaemic neuropathy with fludarabine. J Neurol Neurosurg Psychiatry. 1999;66(5):575–80.CrossRefPubMedPubMedCentral

56.

Gruson B, Ghomari K, Beaumont M, Garidi R, Just A, Merle P, et al. Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy. J Peripher Nerv Syst. 2011;16(3):180–5. doi:10.1111/j.1529-8027.2011.00343.x.CrossRefPubMed

57.

Kyle R, Kelly CM, Dyck PJ. Amyloidosis and Neuropathy. In: Dyck PJ, Thomas P, editors. Peripheral Neuropathy. 4th ed. Philadelphia: Elsevier Saunders; 2005. p. 2427–51.CrossRef

58.

Li J, Zhang W, Jiao L, Duan MH, Guan HZ, Zhu WG, et al. Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome. Blood. 2011;117(24):6445–9. doi:10.1182/blood-2010-12-328112.CrossRefPubMedPubMedCentral

59.

Neurology AA. Treatment of Painful Diabetic Neuropathy. 2011. https://www.aan.com/Guidelines/home/GetGuidelineContent/480. Accessed September 18, 2015.

60.

Carlsson KC, Hoem NO, Moberg ER, Mathisen LC. Analgesic effect of dextromethorphan in neuropathic pain. Acta Anaesthesiol Scand. 2004;48(3):328–36. doi:10.1111/j.0001-5172.2004.0325.x.CrossRefPubMed

61.

Vesole DH, Perez WS, Akasheh M, Boudreau C, Reece DE, Bredeson CN. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study. Mayo Clin Proc. 2006;81(7):880–8. doi:10.4065/81.7.880.CrossRefPubMed

62.

Kuwabara S, Misawa S, Kanai K, Suzuki Y, Kikkawa Y, Sawai S, et al. Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome. Neurology. 2008;71(21):1691–5. doi:10.1212/01.wnl.0000323811.42080.a4.CrossRefPubMed

63.

Costigan DJ, Clouse RE. Achalasia-like esophagus from amyloidosis. Successful treatment with pneumatic bag dilatation. Dig Dis Sci. 1983;28(8):763–5.CrossRefPubMed

64.

Lopez-Cepero Andrada JM, Jimenez Arjona J, Amaya Vidal A, Rubio Garrido J, Navas Relinque C, Soria de la Cruz MJ, et al. Pseudoachalasia and secondary amyloidosis in a patient with rheumatoid arthritis. Gastroenterol Hepatol. 2002;25(6):398–400.CrossRefPubMed

65.

Schroder S, Liepert J, Remppis A, Greten JH. Acupuncture treatment improves nerve conduction in peripheral neuropathy. Eur J Neurol. 2007;14(3):276–81. doi:10.1111/j.1468-1331.2006.01632.x.PubMed

66.

Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood. 2008;111(2):785–9. doi:10.1182/blood-2007-08-1.CrossRefPubMedPubMedCentral

Title: Paraproteinemic neuropathy: a practical review
Authors: Richard A. Rison
Said R. Beydoun
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Neurology / Issue 1/2016
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-016-0532-4

At a glance: The STEP trials

Springer Medicine

Paraproteinemic neuropathy: a practical review

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Critical illness polyneuropathy (CIP) in neurological early rehabilitation: clinical and neurophysiological features

Efficacy and safety of pharmacological treatments for Lyme neuroborreliosis in children: a systematic review

Health-related quality of life in stroke patients questionnaire, short version (HRQOLISP-40): validation for its use in Colombia

Effects of clobazam for treatment of refractory status epilepticus

Help seeking behavior and onset-to-alarm time in patients with acute stroke: sub-study of the preventive antibiotics in stroke study

Comorbid epilepsy in Finnish patients with adult-onset Huntington’s disease